Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of seven systematic review(s)/meta-analysis(es). ^[1-7]
• The FOLFOXIRI regimen combined with panitumumab or cetuximab in metastatic colorectal cancer (mCRC) showed a pooled objective response rate (ORR) of 85% (95% confidence interval (CI), 0.78-0.91) and an R0 resection rate of 42% (95% CI, 0.32-0.53), with median Progression-Free Survival (PFS) ranging from 9.5 to 15.5 months and median overall survival (OS) from 24.7 to 37 months.
• Another meta-analysis on mCRC reported a pooled ORR of 82% (95% CI, 76-88%), a pooled R0 resection rate of 59% (95% CI, 49-68%), with PFS ranging from 9.5 to 17.8 months and OS from 24.7 to 62.5 months.
• Panitumumab increased the objective response rate for wild-type (WT) Kirsten rat sarcoma virus (KRAS) (relative risk (RR) = 1.70; 95% CI, 1.07-2.69) without a significant effect on mutant KRAS (RR = 0.92; 95% CI, 0.79-1.08); it had no significant impact on mortality overall (RR = 0.86; 95% CI, 0.69-1.08) or specifically in WT KRAS (RR = 0.94; 95% CI, 0.84-1.05).
• Common Adverse Events: Grades 3 and 4 adverse events included diarrhea (29%), neutropenia (28%), and skin toxicity (17%) in mCRC populations. Serious adverse events showed elevated risks for thromboembolism (RR 3.65), skin toxicity (RR 15.22), mucositis (RR 3.18), hypomagnesemia (RR 20.10), and dehydration (RR 2.81).
• Panitumumab Supplementation: An increase in grade 3 and 4 adverse events was observed in the panitumumab group (RR = 1.17), with no significantly increased risk of fatal adverse events (FAEs) compared to placebo or blank treatment.
• There is no population types or subgroups information available in the reviewed studies.